Peripheral nervous system

Children's Wisconsin, Froedtert & the Medical College of Wisconsin, the Medical College of Wisconsin and Zablocki VA Medical Center Launch Wisconsin Institute of NeuroScience

Retrieved on: 
Wednesday, February 7, 2024
Partnership, Myelopathy, Clement, Concussion, Neuroscience, School, WINS, Research, Patient, Medical college, Peripheral nervous system, Physician, Brain, Spine, MCW, DCM, Doctor of Philosophy, Rehabilitation, Spinal cord

MILWAUKEE, Feb. 7, 2024 /PRNewswire/ -- Milwaukee is now home to one of the nation's first institutes designed specifically to focus on the neurological needs of people from birth to old age. The Wisconsin Institute of NeuroScience (WINS) is a partnership of Children's Wisconsin, the Froedtert & the Medical College of Wisconsin health network, the Medical College of Wisconsin (MCW) and the Clement J. Zablocki Veterans' Administration Medical Center.

Key Points: 
  • The Wisconsin Institute of NeuroScience (WINS) is a partnership of Children's Wisconsin, the Froedtert & the Medical College of Wisconsin health network, the Medical College of Wisconsin (MCW) and the Clement J. Zablocki Veterans' Administration Medical Center.
  • "Importantly, WINS also will further the groundbreaking research already underway here and increase educational opportunities so we can produce the next generation of neuroscientists."
  • Despite being one of the most common causes of spinal cord injury, public awareness of DCM remains limited.
  • The Center for Cervical Myelopathy aims to fill that void by providing patients, physicians and scientists with resources to advance understanding and treatment of this condition.

Forge Biologics Announces Positive FBX-101 Clinical Trial Update in Patients with Krabbe Disease Identified by Newborn Screening Ahead of RUSP Vote

Retrieved on: 
Monday, January 29, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Mortality, Death, HSCT, Patient, Legislation, GALC, Advisory Committee, AAV, Psychosine, ESGCT, Data, Gene, DSM-IV codes, Neurodegenerative disease, Disease, Safety, Central nervous system, Sphingolipid, Physician, Krabbe disease, Cell, Human services, Parent, Nervous system, Clinical trial, Forge, Peripheral nervous system, Hematopoietic stem cell transplantation, Brain, UCBT, Pharmaceutical industry

Infantile Krabbe patients, often not diagnosed until after significant disease manifestations have occurred, typically die by the age of two if not treated by HSCT before symptoms are observed.

Key Points: 
  • Infantile Krabbe patients, often not diagnosed until after significant disease manifestations have occurred, typically die by the age of two if not treated by HSCT before symptoms are observed.
  • Previously published data have demonstrated that patients with Krabbe treated with HSCT demonstrate increased lifespan and stabilization of neurodegenerative disease in the central nervous system.
  • FBX-101, an investigational adeno-associated viral (AAV) gene therapy, has been designed to address the peripheral nerve disease not corrected by HSCT.
  • As a result, after a year of patient and foundation advocacy, Krabbe disease is again being voted on for potential inclusion on the RUSP.

Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Retrieved on: 
Monday, January 29, 2024
Neurology, Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Clinical Trials, Medication package insert, Patient, CHMP, Immunodeficiency, Nausea, Itch, PID, Erythema, Civil service commission, European Commission, Edema, Research and development, Aes, Recombinant, Skin, Food, Disease, Safety, Primary immunodeficiency, Committee, Absorption, IVIG, Peripheral nervous system, Headache, Diagnosis, Pharmaceutical industry

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy (CIDP) after stabilization with intravenous immunoglobulin therapy (IVIG).

Key Points: 
  • Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy (CIDP) after stabilization with intravenous immunoglobulin therapy (IVIG).
  • The majority of AEs were mild or moderate, local, did not require suspension of infusions, and resolved without sequelae.
  • The most common (reported in >5% of patients) causally related AEs included headache and nausea, as well as local AEs including infusion site pain, erythema, pruritis, and edema.
  • HYQVIA first received approval from the EC for the treatment of primary immunodeficiency (PID) in 2013 as well as secondary immunodeficiency (SID) in 2020.8

Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)

Retrieved on: 
Thursday, January 4, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Other Health, Psychiatry, XETRA, ADOS, Medication, Positive, Incidence, Clinical Global Impression, CNS, Molecular medicine, PANSS, EKG, Weight gain, Longevity, Peripheral nervous system, TRS, Patient, Pharmaceutical industry

The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.

Key Points: 
  • The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.
  • In contrast to common clinical experience, no patient “relapsed” during the one-year treatment period.
  • Ravi Anand, Newron’s Chief Medical Officer, said: “Treatment with evenamide as an add-on to antipsychotics in TRS patients has produced benefits that have never been reported before.
  • The presentation for this conference call can be downloaded as of today, January 4, 2024, at 7 am CET, on Newron’s website ( https://www.newron.com/investors/reports-and-presentation/year/2024 ).

EQS-News: Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)

Retrieved on: 
Thursday, January 4, 2024
Psychiatry, XETRA, ADOS, Positive, Incidence, Clinical Global Impression, CNS, Molecular medicine, PANSS, EKG, Weight gain, Longevity, Peripheral nervous system, TRS, Patient, Pharmaceutical industry

The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.

Key Points: 
  • The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.
  • In contrast to common clinical experience, no patient “relapsed” during the one-year treatment period.
  • 25% of all patients achieved “remission” (see “About remission”), never described before in TRS patients.
  • The presentation for this conference call can be downloaded as of today, January 4, 2024, at 7 am CET, on Newron’s website ( https://www.newron.com/investors/reports-and-presentation/year/2024 ).

Newron Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A With Evenamide

Retrieved on: 
Friday, December 29, 2023
Science, Neurology, Other Science, Biotechnology, Pharmaceutical, General Health, Health, Mental Health, Peripheral nervous system, Patient, Medication, Safety, XETRA, Schizophrenia, Pharmaceutical industry

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the completion of patient enrollment in study 008A, its potentially pivotal study with evenamide in patients suffering from schizophrenia.

Key Points: 
  • Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the completion of patient enrollment in study 008A, its potentially pivotal study with evenamide in patients suffering from schizophrenia.
  • Study 008A is a four-week, randomized, double-blind and placebo-controlled study assessing the efficacy, tolerability, and safety of evenamide (30 mg bid) in patients with chronic schizophrenia currently being treated with a second-generation antipsychotic, but who demonstrate an inadequate response to that treatment.
  • A total of 290 patients were enrolled at study centers in Europe, Asia and Latin America.
  • If positive, study 008A would be the first well-controlled study to demonstrate the clinical utility of evenamide in schizophrenia patients who show an inadequate response to treatment with atypical antipsychotics.

EQS-News: Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide

Retrieved on: 
Saturday, December 30, 2023
Peripheral nervous system, Patient, Safety, XETRA, Schizophrenia, Pharmaceutical industry

290 patients participate at study centers in Europe, Asia and Latin America

Key Points: 
  • 290 patients participate at study centers in Europe, Asia and Latin America
    Milan, Italy, December 29, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the completion of patient enrollment in study 008A, its potentially pivotal study with evenamide in patients suffering from schizophrenia.
  • Study 008A is a four-week, randomized, double-blind and placebo-controlled study assessing the efficacy, tolerability, and safety of evenamide (30 mg bid) in patients with chronic schizophrenia currently being treated with a second-generation antipsychotic, but who demonstrate an inadequate response to that treatment.
  • A total of 290 patients were enrolled at study centers in Europe, Asia and Latin America.
  • If positive, study 008A would be the first well-controlled study to demonstrate the clinical utility of evenamide in schizophrenia patients who show an inadequate response to treatment with atypical antipsychotics.

Autonomix Medical, Inc. to Participate in the Virtual Investor Fireside Chat

Retrieved on: 
Thursday, December 14, 2023
Virtual, Peripheral nervous system, Nervous system

THE WOODLANDS, TX, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Lori Bisson, Chief Executive Officer of Autonomix, will participate in the Virtual Investor Fireside Chat featuring Autonomix on Tuesday, December 19, 2023 at 3:00 PM ET.

Key Points: 
  • As part of the event, management will discuss the Company’s innovative technologies in development to revolutionize how diseases involving the peripheral nervous system are diagnosed and treated.
  • In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event.
  • A live video webcast of the fireside chat will be available on the Events page of the Company’s website ( autonomix.com ).
  • A webcast replay will be available two hours following the live event and will be accessible for 90 days.

Autonomix Medical, Inc. to Present at the Virtual Investor Event Titled “A Breakthrough Medical Device for the Diagnosis and Treatment of Diseases of the Nervous System”

Retrieved on: 
Wednesday, December 6, 2023
Virtual, Diagnosis, Peripheral nervous system, Disease, Treatment, Nervous system, Broadcasting

THE WOODLANDS, TX, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will present at the Virtual Investor: A Breakthrough Medical Device for the Diagnosis and Treatment of Diseases of the Nervous System event on Monday, December 11, 2023 at 2:00 PM ET.

Key Points: 
  • As part of the event, Lori Bisson, Chief Executive Officer of Autonomix will discuss its innovative technologies in development to revolutionize how diseases involving the peripheral nervous system are diagnosed and treated.
  • In addition to the moderated discussion, interested parties will have the opportunity to submit questions live during the event.
  • A live video webcast of the presentation will be available on the Events page of the Company’s website ( autonomix.com ).
  • A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

Autonomix Medical, Inc. Announces Appointment of Christopher C. Capelli, M.D. to Board of Directors

Retrieved on: 
Thursday, November 16, 2023
Coloplast, Peripheral nervous system, Technology management, MIT, University, Mechanical engineering, RAP, Pain management, University of Pittsburgh, Nervous system, AbbVie, Medical device, Science, Massachusetts Institute of Technology, MD, Knowledge, Patent

“We are pleased to welcome Dr. Capelli to our board of directors.

Key Points: 
  • “We are pleased to welcome Dr. Capelli to our board of directors.
  • He brings with him a wealth of knowledge and expertise, amassed over a noteworthy career.
  • Dr. Capelli currently serves as the Scientific Officer & Medical Device Advisor-Soliton for Allergan Aesthetics R&D Surgical Devices at AbbVie.
  • As a businessman, Dr. Capelli has been directly involved in the start-up of numerous venture-capital backed biomedical company ventures.